|
|
Volumn 8, Issue 7, 2007, Pages 564-565
|
|
Radium-223 for men with hormone-refractory prostate cancer and bone metastases
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
DOCETAXEL;
PLACEBO;
PREDNISONE;
PROSTATE SPECIFIC ANTIGEN;
RADIOISOTOPE;
RADIUM;
RADIUM 223;
STRONTIUM 89;
TUMOR MARKER;
UNCLASSIFIED DRUG;
BLOOD TOXICITY;
BONE METASTASIS;
BONE PAIN;
CANCER PATIENT;
CANCER SURVIVAL;
CLINICAL STUDY;
CLINICAL TRIAL;
CONSTIPATION;
DRUG DOSE COMPARISON;
DRUG MEGADOSE;
DRUG TOLERABILITY;
HUMAN;
LETTER;
MULTIPLE CYCLE TREATMENT;
NEUROLOGIC DISEASE;
NEUTROPENIA;
OVERALL SURVIVAL;
PATHOLOGIC FRACTURE;
PRIORITY JOURNAL;
PROSTATE CANCER;
QUALITY OF LIFE;
RADIATION DOSE FRACTIONATION;
SIDE EFFECT;
SINGLE DRUG DOSE;
STATISTICAL ANALYSIS;
SURVIVAL RATE;
TREATMENT OUTCOME;
ALKALINE PHOSPHATASE;
BONE NEOPLASMS;
DRUG RESISTANCE, NEOPLASM;
HUMANS;
MALE;
PROGNOSIS;
PROSTATE-SPECIFIC ANTIGEN;
PROSTATIC NEOPLASMS;
RADIUM;
|
|
EID: 34347204847
PISSN: 14702045
EISSN: None
Source Type: Journal
DOI: 10.1016/S1470-2045(07)70180-8 Document Type: Letter |
|
Times cited : (5)
|
|
References (8)
|
